PRTC News and Press, PureTech Health plc From 04/28/23

Strong capital base with PureTech level cash, cash equivalents and short-term investments of $339.5 million 1 and consolidated cash, cash equivalents and short-term investments of $350.1 million, 2 as of December 31, 2022. Rapid advancement of PureTech’s Wholly Owned Pi...

2023-04-25 07:20:10 ET PureTech Health ( NASDAQ: PRTC ) said its founded entity Vedanta Biosciences has raised $106.5M to support development of its drug pipeline. The funds are aimed to help advance the company's lead drug VE303 in a phase 3 trial for preventing recurrent Clo...

Financing will enable pivotal Phase 3 study of VE303 for recurrent C. difficile infection, to begin by 3Q 2023 Funds will also support Phase 2 study of VE202 for ulcerative colitis, to begin in 2Q 2023 Syndicate led by new investors AXA IM Alts and The AMR Action Fund alon...

JAMA publication includes in-depth safety and efficacy results from Vedanta’s successful Phase 2 study of VE303 PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today t...

Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds PureTech retains its current equity stake in Karuna in addition to milestone payments and 20...

Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT ; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds. PureTech retains its current equity stake in Karuna in addition to milesto...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that Bharatt Chowrira, Ph.D., J.D., President and Chief Business, Finance and Operating Of...

Project to leverage vocal biomarkers for cognitive assessment of patients ages 55 and above in home environment PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Fou...

A placebo-controlled, Phase 2a, proof-of-concept, social anxiety clinical trial in healthy volunteers is expected to begin in the first half of 2023, with results anticipated by the end of 2023 An open-label, Phase 2a, proof-of-concept clinical trial in women with postpartum depression is...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that Daphne Zohar, Founder and Chief Executive Officer and Eric Elenko, Chief Innovation O...